Field
The present invention relates generally to catheters. More particularly, the present invention relates to a nephroureteral catheter.
Many patients experience the development of a stricture or blockage within the ureter of one or both kidneys. The ureter is the muscular tube that connects the kidney to the bladder. As urine is made by the kidney it drains into a central collecting system of the kidney and then travels though the ureter into the bladder. Patients can develop strictures, or blockages, of the ureter due to kidney stones, cancers, infections, trauma, and prior medical instrumentations. In rare instances, some children are born with blockages of one or both ureters. If untreated, the blockage will eventually lead to kidney failure.
Regardless the cause, the treatment for a blocked ureter is to relieve the blockage. Blockage removal is performed by inserting a long tube to connect the collecting system of the kidney to the bladder. This tube is called a stent and is placed through the ureter.
Stent insertion is typically performed by one of two methods. The stent may be inserted urologically. With this method, a scope is advanced through the urethra into the bladder. A wire is then inserted into the ureter in a retrograde fashion, using the scope to thread the wire. When the wire reaches the collecting system of the kidney, a plastic stent is inserted over the wire. The stent is a straight plastic tube that has a pigtail-shaped curl on each end. Once in place, the wire is removed and the scope is taken out of the bladder. One pigtail curl of the stent resides in the collecting system of the kidney and the other resides in the bladder. The straight portion of the stent traverses the ureter. This is performed using direct visualization with the scope and also with fluoroscopic guidance. The stent usually stays in for a period of approximately three months, at which point the stent is then swapped out for a new stent by the urologist using a similar technique.
The second method for insertion is to insert the stent percutaneously. This method is typically performed in stages. The right or left flank of the patient is sterilely prepared depending upon which kidney is to be accessed (sometimes both are accessed to treat bilateral blockages). Intravenous sedation is used. A small bore needle is used to puncture the collecting system of the kidney and contrast is injected allowing the complete visualization of the entire collecting system. The central portion is initially punctured with a small needle, and then a larger needle is used to puncture a smaller but safer area of the collecting system. A guidewire is threaded into the collecting system of the kidney and a pigtail drain, or nephrostomy catheter, is placed, sutured to the back, and hooked up to a bag for external drainage. Once the urine has cleared from bleeding, the patient is brought back to the angiography table, placed prone, and a wire is inserted through the catheter into the kidney. The catheter is then removed. The wire is threaded through the ureter into the bladder (across the stricture) and a nephroureteral catheter is placed.
A nephroureteral catheter is a long plastic tube that goes from the outside of the patient into the kidney's collecting system, through the ureter, and into the bladder. The catheter allows drainage of urine into the bladder and externally into a bag. The catheter typically stays in the patient for 7-10 days, at which time the patient is brought back to the angiography table and a wire is threaded through this tube into the bladder. The tube is removed and an internal stent is placed using fluoroscopic guidance. This is the same type of stent that is placed by the urologist working through the bladder. This can be a complex and difficult procedure.
In accordance with the present invention, a nephroureteral catheter is provided that comprises a detachable portion such that when the detachable portion is removed, the catheter converts into an internal stent.
The catheter includes a tube having a circular cross section, a first end, a second end, a first retention feature near the first end, and a second retention feature near the second end. The catheter also comprises a detachable portion, wherein the detachable portion is in fluid communication with and is removably attachable to the tube at the second end, an inner tube comprising at least one lumen, wherein the inner tube is removably insertable into both the tube and the detachable portion, and a wire extending through at least a portion of a lumen of the at least one lumen of the inner tube. A portion of the wire is attached to the tube.
The convertible nephroureteral catheter eliminates the step of removing a nephroureteral catheter and placing a new internal stent into a patient. Because a step is eliminated, the convertible nephroureteral catheter saves time. Instead of a physician having to take steps such as sterile prep to place a new catheter inside a patient, the physician need only unlock the hub of the convertible nephroureteral catheter to detach the external portion of the catheter. Money is also saved since one less catheter will be required. In addition, other supplies such as wires, sheaths, and other equipment needed to place a typical internal catheter will be spared. The patient will only be subjected to minimal, if any, radiation from fluoroscopy.
The convertible nephroureteral catheter will also result in less patient discomfort, again due to minimal manipulation because less steps are required. With previous stent insertion procedures, local and IV sedation and nursing monitoring were required.
Patients will not require sedation for the process of removing the removable portion of the convertible nephroureteral catheter. The new procedure for transforming the convertible nephroureteral catheter may be performed at bedside.
The convertible nephroureteral catheter allows for the catheter insertion process to be a single step instead of a multiple-step process. The ability to insert a catheter percutaneously with a single step might provide an advantage over urological insertion, as they will both now require only a single step for insertion, yet using the convertible nephroureteral catheter will not require the general anesthesia required by urological insertion.
Various embodiments are described herein with reference to the following drawings. Certain aspects of the drawings are depicted in a simplified way for reason of clarity. Not all alternatives and options are shown in the drawings and, therefore, the invention is not limited in scope to the content of the drawings. In the drawings:
Catheter 100 allows for the drainage of urine into the bladder and externally into a bag. Catheter 100 includes a tube 110 having a circular cross section 120, a detachable portion 130, a locking mechanism 140, an inner tube 150, a first pigtail curl 160, a second pigtail curl 170, and a marker 190. Catheter 100 also includes a first end 112, a second end 114, and a plurality of holes 116. When detachable portion 130 is attached to the catheter, catheter 100 is a nephroureteral catheter. When detachable portion 130 is removed from the catheter, the catheter becomes a stent 200, as shown in
Tube 110 may be flexible. The tube 110 has a hollow interior or lumen to allow for fluids to flow through the tube. A plurality of holes 116 extend through tube 110 so that fluids may flow into or out of tube 110 through the holes. Tube 110 is of sufficient length so that it extends from the outside of the patient into the kidney, through the ureter and into the bladder.
First pigtail curl 160 and second pigtail curl 170 serve the purpose of retaining or keeping tube 110 in the proper position within the patient. First pigtail curl 160 is located near first end 112 and second pigtail curl 170 is near second end 114, so that first pigtail curl 160 lies within the collecting system of the kidney and second pigtail curl 170 lies within the bladder. Each curl serves as a retention feature and ensures tube 110 will not move out of the ureter, because each curl is too large to pass through the ureter. Second pigtail curl 170 enters the ureter in a straight position, but the material of tube 110 at the section of second pigtail curl room to bend, or once it has exited the ureter.
First pigtail curl 170 is such that it will bend into the curl position shown in
Locking mechanism 140 may be a number of locking mechanisms currently used in the art. Locking mechanism closes off detachable portion 130 of tube 110, and may be manually opened and removed to access any of detachable portion 130, inner tube 150, or tube 110.
Detachable portion 130 may be made from the same material as tube 110. Detachable portion 130 may be flush with tube 110 at marker 190. Detachable portion 130 comprises a hollow section within which inner tube 150 may slide through. Inner tube may extend through a portion of tube 110, as shown in
Detachable portion 130 may be manufactured as part of catheter 100. When attached to catheter 100 and in place inside a patient, detachable portion 130 extends from the center of the kidney to an exit in the back of the patient, ending with locking mechanism 140, which is located outside the patient's body.
In another example embodiment, an inner tube portion 250 and a wire 255 may extend through both detachable portion 230 and the tube 210, as shown in
Detachable portion 230 may be manufactured as part of catheter 200. When attached to catheter 200 and in place inside a patient, detachable portion 230 extends from the center of the kidney to an exit in the back of the patient, ending with locking mechanism 240, which is located outside the patient's body.
The wire 255 may be affixed to and then removed at the locking mechanism 240 to disconnect the distal section of inner tube 250 from tube 210, rendering the catheter 200 a stent, as will be described with further detail below. The locking mechanism may comprise a luer lock, for example. Other locking mechanisms may also be envisioned. Such a locking mechanism may be affixed via any of a number of bonding or fastening methods.
Wire 255 may comprise a material that has sufficient tensile strength to hold inner tube 250 and tube 210 together, such as a metallic composite material. Example metallic composite materials that may be used are stainless steel, Elgiloy, a nickel cobalt alloy (e.g., MP35N), or a nickel titanium alloy (e.g., Nitinol), for example.
To connect the detachable portion 230 to tube 210, wire 255 may be sent through inner tube 250, which may contain one or more lumens.
In an alternative embodiment shown in
An inner tube 450 may comprise two lumens, first lumen 451 and second lumen 452. First lumen 451 may comprise a wall to separate first lumen 451 from second lumen 452. A wire 455, which may take the form of either wire 255 or wire 355, may run through first lumen 451 and thus be isolated within lumen 451 so as not to interfere with second lumen 452. Second lumen 452 may serve as a wire guide or stent straightening lumen. The dual lumen feature of inner tube 450 permits the use of an isolated access pathway (second lumen 452) to be used for device tooling such as a wire guide or stent straightener without risk of disrupting wire 455 located within lumen 451. First lumen 451 provides a protective safeguard against dislodgement of wire 455 during implantation of the catheter within patient and during the corresponding exchange of catheter tooling during intervention. Fluid may be exchanged between catheter 400 and inner tube 450 via both first lumen 451 and second lumen 452.
Detachable portion 530 may comprise a first tube portion 532, a second tube portion 534, and a transition 536 from the first tube portion 532 to the second tube portion 534. Transition 536 may take the form of a step and may comprise about a 90 degree transition. A lumen 533 may extend through both the first tube portion 532 and the second tube portion 534 as shown, and may comprise the same diameter through both portions. Transition 536 may mate with or abut an end 505 of catheter 500. Second tube portion 534 comprises a smaller diameter than the first tube portion 532, and is sized and shaped to fit within the lumen of the catheter 500. Such a design for detachable portion 530 renders having an additional inner tube, such as inner tubes 150 and 250, for example, unnecessary.
In operation, the right or left flank of the patient is sterilely prepared depending upon which kidney is to be accessed. Intravenous sedation is used. A small bore needle is used to puncture the collecting system of the kidney and contrast is injected allowing the complete visualization of the entire collecting system. The central portion is initially punctured with a small needle, and then a larger needle is used to puncture a smaller but safer area of the collecting system. A guidewire is threaded into the collecting system of the kidney and a pigtail drain, or nephrostomy catheter, is placed, sutured to the back, and hooked up to a bag for external drainage.
Once the urine has cleared from bleeding, the patient is brought back and a wire is inserted through the catheter into the kidney and the catheter is removed. The wire is threaded through the ureter into the bladder (across the stricture) and catheter 100 is placed. Pigtail curls 160, 170 are curled to their proper position. The catheter typically stays in the patient for 7-10 days, at which time the patient is brought back.
At this point, if the physician desires to exchange the catheter 100 for a stent 200, the physician will unlock locking mechanism 140, and will remove the locking mechanism to access inner tube 150. The physician will then manually pull inner tube 150 through the hollow portion of tube 110 toward first end 112, until inner tube 150 has been pulled past marker 190 and is no longer within the hollow portion of tube 110.
In another example embodiment, wherein a wire is used, such as described with reference to
Once inner tube 150 has been removed from tube 110, detachable portion 130 is no longer attached to tube 110 and both detachable portion 130 and inner tube 150 may be removed from the patient's body. Once detachable portion 130 and inner tube 150 are removed, catheter 100 becomes a stent 200, as shown in
An example of when the convertible nephroureteral catheter may be used is a situation in which a patient has a blockage of the ureter and presents with hydronephrosis (dilation of the kidney's collecting system) and hydroureter (dilation of the ureter). The patient has a device inserted through the flank, into the collecting system, and through the ureter into the bladder. The device will be left open to external drainage until the urine clears from infection or bleeding. When the urine has cleared, the external portion of the convertible nephroureteral catheter 100 will be detached, converting the catheter into an internal stent. From this point forward, the stent will drain urine directly from the kidney to the bladder. The internal stent will remain in place until it is ready to be removed or replaced.
Another example of use is when a patient recently passed a kidney stone and the ureter is temporarily inflamed and blocked. The convertible nephroureteral catheter is inserted in the same manner described above. In this situation, however, the catheter is in place temporarily until the inflammation improves; once this is confirmed, the entire catheter is removed by pulling it out of the flank with contrast injection under fluoroscopy. In this situation the detachable portion is not detached. However, the catheter may also be left in place as an internal stent, and the detachable portion removed, depending on the clinical need.
Another example of use is when a patient has leakage from the ureter due to trauma, instrumentation, stone removal, cancer, or another reason, and internal and external urine diversion is necessary. In this case, convertible nephroureteral catheter 100 is placed in the patient and urine is allowed to drain externally. When there is improvement in the leakage and the catheter is converted to an internal stent by removing detachable portion 130, internal urine diversion is allowed for a longer period of time. The stent 500 will be removed at a later date after the leak is resolved.
It will thus be seen that certain changes may be made in the above constructions without departing from the spirit and scope of the invention. It is intended that all matter contained in the above description or shown in the accompanying drawings shall be interpreted as illustrative and not in a limiting sense.
This application is a continuation of U.S. patent application Ser. No. 15/175,436, filed Jun. 7, 2016 (now issued as U.S. Pat. No. 10,695,161 on Jun. 30, 2020), which is a divisional of U.S. patent application Ser. No. 14/159,221 (now issued as U.S. Pat. No. 9,387,312 on Jul. 12, 2016), filed Jan. 20, 2014, which is a continuation-in-part of U.S. patent application Ser. No. 12/559,946 (now issued as U.S. Pat. No. 8,657,884 on Feb. 25, 2014), filed Sep. 15, 2009, which claims the benefit of U.S. Provisional Application Ser. No. 61/096,902, filed Sep. 15, 2008, the contents of all of which are fully incorporated herein by reference.
Number | Name | Date | Kind |
---|---|---|---|
818817 | Leva | Apr 1906 | A |
3996938 | Clark, III | Dec 1976 | A |
4350161 | Davis, Jr. | Sep 1982 | A |
4790810 | Pugh, Jr. et al. | Dec 1988 | A |
4813925 | Anderson, Jr. | Mar 1989 | A |
4830003 | Wolff et al. | May 1989 | A |
4913683 | Gregory | Apr 1990 | A |
4957479 | Roemer | Sep 1990 | A |
5002560 | Machold et al. | Mar 1991 | A |
5019090 | Pinchuk | May 1991 | A |
5071407 | Termin et al. | Dec 1991 | A |
5122136 | Guglielmi et al. | Jun 1992 | A |
5221253 | Coll | Jun 1993 | A |
5250069 | Nobuyoshi et al. | Oct 1993 | A |
5259847 | Trambert | Nov 1993 | A |
5282784 | Willard | Feb 1994 | A |
5354263 | Coll | Oct 1994 | A |
5364340 | Coll | Nov 1994 | A |
5456667 | Ham et al. | Oct 1995 | A |
5507732 | McClure et al. | Apr 1996 | A |
5507751 | Goode et al. | Apr 1996 | A |
5599291 | Balbierz et al. | Feb 1997 | A |
5643254 | Scheldrup et al. | Jul 1997 | A |
5653684 | Laptewicz et al. | Aug 1997 | A |
5846251 | Hart | Dec 1998 | A |
5876417 | Devonec et al. | Mar 1999 | A |
5921952 | Desmond, III et al. | Jul 1999 | A |
5964771 | Beyar | Oct 1999 | A |
6074339 | Gambale et al. | Jun 2000 | A |
6196996 | Teirstein | Mar 2001 | B1 |
6248100 | De et al. | Jun 2001 | B1 |
6264624 | Desmond, III et al. | Jul 2001 | B1 |
6319287 | Frimberger | Nov 2001 | B1 |
6562024 | Toledo et al. | May 2003 | B2 |
6569150 | Teague et al. | May 2003 | B2 |
6576008 | Devonec et al. | Jun 2003 | B2 |
6629981 | Bui et al. | Oct 2003 | B2 |
6673106 | Mitelberg et al. | Jan 2004 | B2 |
6676651 | Haacke et al. | Jan 2004 | B2 |
6913625 | Segura et al. | Jul 2005 | B2 |
6929664 | Kolb et al. | Aug 2005 | B2 |
6949125 | Robertson | Sep 2005 | B2 |
6991614 | McWeeney et al. | Jan 2006 | B2 |
7044980 | Hammond et al. | May 2006 | B2 |
7044981 | Liu et al. | May 2006 | B2 |
7169139 | Teague et al. | Jan 2007 | B2 |
7217250 | Kolb et al. | May 2007 | B2 |
7367987 | Balgobin et al. | May 2008 | B2 |
7371252 | Balgobin et al. | May 2008 | B2 |
7377932 | Mitelberg et al. | May 2008 | B2 |
7550002 | Goto et al. | Jun 2009 | B2 |
7566316 | McGuckin, Jr. et al. | Jul 2009 | B2 |
7722604 | Brown, III et al. | May 2010 | B2 |
7731676 | Maeda | Jun 2010 | B2 |
7811305 | Balgobin et al. | Oct 2010 | B2 |
7824367 | Accisano, III | Nov 2010 | B2 |
7901444 | Slazas | Mar 2011 | B2 |
7901704 | Richard | Mar 2011 | B2 |
7993329 | Howell et al. | Aug 2011 | B2 |
8007540 | Robertson | Aug 2011 | B2 |
8021434 | Segura et al. | Sep 2011 | B2 |
8034094 | Aoba et al. | Oct 2011 | B2 |
8070825 | Devonec | Dec 2011 | B2 |
8298276 | Ozawa et al. | Oct 2012 | B2 |
8333000 | Huang et al. | Dec 2012 | B2 |
8333796 | Tompkins et al. | Dec 2012 | B2 |
8603185 | Shah et al. | Dec 2013 | B2 |
8657884 | Smouse | Feb 2014 | B2 |
8676349 | Stalker et al. | Mar 2014 | B2 |
8702784 | Weisman et al. | Apr 2014 | B2 |
8753303 | Weisman et al. | Jun 2014 | B2 |
8771335 | Griego et al. | Jul 2014 | B2 |
8961518 | Taylor et al. | Feb 2015 | B2 |
8961581 | Hollett et al. | Feb 2015 | B2 |
8979824 | Amos et al. | Mar 2015 | B2 |
8986364 | Okuma | Mar 2015 | B2 |
9026229 | Stalker et al. | May 2015 | B2 |
9186151 | Tompkins et al. | Nov 2015 | B2 |
9265637 | Weisman et al. | Feb 2016 | B2 |
9308359 | Ward | Apr 2016 | B2 |
9314359 | Windheuser et al. | Apr 2016 | B2 |
9387312 | Smouse | Jul 2016 | B2 |
9510962 | Aoba et al. | Dec 2016 | B2 |
9517120 | Devonec et al. | Dec 2016 | B2 |
9597207 | Weisman et al. | Mar 2017 | B2 |
9956100 | Smouse et al. | May 2018 | B2 |
20030069533 | Kakutani et al. | Apr 2003 | A1 |
20030163204 | Rix | Aug 2003 | A1 |
20030191450 | Teague et al. | Oct 2003 | A1 |
20030195456 | Robertson | Oct 2003 | A1 |
20040073283 | Ewers | Apr 2004 | A1 |
20040098105 | Stinson et al. | May 2004 | A1 |
20040181186 | Gellman et al. | Sep 2004 | A1 |
20040249343 | Cioanta | Dec 2004 | A1 |
20050085892 | Goto et al. | Apr 2005 | A1 |
20070078446 | Lavelle | Apr 2007 | A1 |
20070112420 | Laduca | May 2007 | A1 |
20070233223 | Styrc et al. | Oct 2007 | A1 |
20070276466 | Lavelle et al. | Nov 2007 | A1 |
20080109059 | Gordon et al. | May 2008 | A1 |
20080140101 | Carley et al. | Jun 2008 | A1 |
20080221554 | O'Connor et al. | Sep 2008 | A1 |
20090048654 | Chmura et al. | Feb 2009 | A1 |
20090088833 | Soetermans | Apr 2009 | A1 |
20090099640 | Weng | Apr 2009 | A1 |
20090105719 | Honey et al. | Apr 2009 | A1 |
20090248169 | Li | Oct 2009 | A1 |
20090312829 | Aoba et al. | Dec 2009 | A1 |
20100070047 | Smouse | Mar 2010 | A1 |
20100185271 | Zhang | Jul 2010 | A1 |
20100268201 | Tieu et al. | Oct 2010 | A1 |
20110009950 | Grandfield et al. | Jan 2011 | A1 |
20110077622 | Weisman et al. | Mar 2011 | A1 |
20110130821 | Styrc | Jun 2011 | A1 |
20110190862 | Bashiri et al. | Aug 2011 | A1 |
20110196410 | Besselink et al. | Aug 2011 | A1 |
20110196507 | St. Pierre | Aug 2011 | A1 |
20110282249 | Tsoref et al. | Nov 2011 | A1 |
20110282429 | Shin et al. | Nov 2011 | A1 |
20110288624 | Roeder et al. | Nov 2011 | A1 |
20110313404 | Amos et al. | Dec 2011 | A1 |
20120041538 | White et al. | Feb 2012 | A1 |
20120095567 | Weisman et al. | Apr 2012 | A1 |
20120203325 | Weisman et al. | Aug 2012 | A1 |
20120330397 | Harrison et al. | Dec 2012 | A1 |
20130110042 | Humphreys et al. | May 2013 | A1 |
20130254751 | Howard | Sep 2013 | A1 |
20140114431 | Yamagata | Apr 2014 | A1 |
20140135941 | Smouse et al. | May 2014 | A1 |
20140172065 | Lavelle et al. | Jun 2014 | A1 |
20140194970 | Chobotov | Jul 2014 | A1 |
20140200462 | Stalker et al. | Jul 2014 | A1 |
20140309721 | Griego et al. | Oct 2014 | A1 |
20150005864 | Okuma | Jan 2015 | A1 |
20150073525 | Aoba et al. | Mar 2015 | A1 |
20150157480 | Amos et al. | Jun 2015 | A1 |
20150223953 | Pendleton et al. | Aug 2015 | A1 |
20160015509 | Mcdonough | Jan 2016 | A1 |
20160045347 | Smouse et al. | Feb 2016 | A1 |
20160120675 | Weisman et al. | May 2016 | A1 |
20160135941 | Binmoeller et al. | May 2016 | A1 |
20160151615 | Overtoom | Jun 2016 | A1 |
20160184123 | Windheuser et al. | Jun 2016 | A1 |
20160287372 | Smouse et al. | Oct 2016 | A1 |
20160361167 | Tuval et al. | Dec 2016 | A1 |
20180325709 | Tatalovich et al. | Nov 2018 | A1 |
20210007870 | Smouse et al. | Jan 2021 | A1 |
Number | Date | Country |
---|---|---|
2128148 | Mar 1993 | CN |
2408894 | Dec 2000 | CN |
201624817 | Nov 2010 | CN |
102548505 | Jul 2012 | CN |
102579171 | Jul 2012 | CN |
102596083 | Jul 2012 | CN |
202537720 | Nov 2012 | CN |
202637201 | Jan 2013 | CN |
103211671 | Jul 2013 | CN |
103876872 | Jun 2014 | CN |
103961194 | Aug 2014 | CN |
2002071765 | Mar 2002 | JP |
2003530165 | Oct 2003 | JP |
2009297502 | Dec 2009 | JP |
2012239803 | Dec 2012 | JP |
201507357 | Apr 2015 | JP |
1988005317 | Jul 1988 | WO |
WO-8805317 | Jul 1988 | WO |
199611721 | Apr 1996 | WO |
2013003450 | Jan 2013 | WO |
WO-201 5108609 | Jul 2015 | WO |
WO-201 6025434 | Feb 2016 | WO |
WO-2016042150 | Mar 2016 | WO |
WO-2018156650 | Aug 2018 | WO |
Entry |
---|
Co-pending U.S. Appl. No. 15/901,833, filed Feb. 21, 2018. |
Co-pending U.S. Appl. No. 15/936,856, filed Mar. 27, 2018. |
U.S. Appl. No. 14/823,243 Notice of Allowance dated Mar. 26, 2018. |
Office Action dated Sep. 9, 2019 for U.S. Appl. No. 15/175,436. |
European Search Report and Search Opinion dated Sep. 7, 2017 for European Patent Application No. 14878890.4. |
European search report and search opinion dated Dec. 22, 2017 for EP Application No. 15831895.6. |
International search report and written opinion dated Jan. 7, 2016 for PCT Application No. PCT/US15/44580. |
International search report and written opinion dated Mar. 25, 2015 for PCT Application No. PCT/US2014/063758. |
Notice of allowance dated Jan. 16, 2018 for U.S. Appl. No. 14/823,243. |
Notice of allowance dated May 13, 2016 for U.S. Appl. No. 14/159,221. |
Notice of allowance dated Oct. 9, 2013 for U.S. Appl. No. 12/559,946. |
Office action dated Jan. 3, 2012 for U.S. Appl. No. 12/559,946. |
Office action dated Feb. 26, 2016 for U.S. Appl. No. 14/159,221. |
Office action dated Apr. 18, 2017 for U.S. Appl. No. 14/823,243. |
Office Action dated Aug. 31, 2017 for U.S. Appl. No. 14/823,243. |
Office action dated Oct. 7, 2015 for U.S. Appl. No. 14/159,221. |
Office action dated Oct. 24, 2012 for U.S. Appl. No. 12/559,946. |
“International Search Report and Written Opinion dated Jun. 15, 2018 for International PCT Patent Application No. PCT/US18/19045”. |
Office Action dated Dec. 31, 2019 for U.S. Appl. No. 15/175,436. |
European Search Report dated May 19, 2020 for EP15831895.6. |
Notice of Allowance dated Apr. 20, 2020 for U.S. Appl. No. 15/936,856. |
Notice of Allowance dated Apr. 27, 2020 for U.S. Appl. No. 15/175,436. |
Office Action dated Jan. 10, 2020 for U.S. Appl. No. 15/936,856. |
Office Action dated Feb. 12, 2020 for U.S. Appl. No. 15/901,833. |
Office Action dated Sep. 19, 2019 for U.S. Appl. No. 15/901,833. |
European Search Report dated Dec. 22, 2020 for EP18758123.6. |
Office Action dated Sep. 4, 2020 for U.S. Appl. No. 15/901,833. |
Office Action dated Feb. 5, 2021 for U.S. Appl. No. 15/901,833. |
Office Action dated May 28, 2021 for U.S. Appl. No. 15/901,833. |
International Search Report and Written Opinion dated Jul. 26, 2021 for PCT/US2021/026886. |
Number | Date | Country | |
---|---|---|---|
20180235744 A1 | Aug 2018 | US |
Number | Date | Country | |
---|---|---|---|
61096902 | Sep 2008 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 14159221 | Jan 2014 | US |
Child | 15175436 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 15175436 | Jun 2016 | US |
Child | 15958406 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 12559946 | Sep 2009 | US |
Child | 14159221 | US |